Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association Between Coagulation Function and Spontaneous Hemorrhagic Transformation in Acute Ischemic Stroke

Author(s): Chen Ye*, Yanan Wang, Quhong Song, Junfeng Liu, Chenchen Wei and Ming Liu

Volume 17, Issue 4, 2020

Page: [344 - 353] Pages: 10

DOI: 10.2174/1567202617666200514114258

Price: $65

Abstract

Background and Purpose: Hemorrhagic transformation (HT) has an adverse effect on the prognosis of patients with acute ischemic stroke, and it is currently known associated with coagulation system. But the conclusion is not consistent and remains to be identified. The aim of this study was to investigate the association between coagulation function and spontaneous hemorrhagic transformation.

Methods: Patients within 7 days from the onset of ischemic stroke who did not receive reperfusion therapy (thrombolysis or endovascular treatment) were included between January 2016 and October 2017. Coagulation function indicators, including prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), thrombin time (TT) and fibrinogen (FIB), were tested within 24 h after admission. HT was defined as hemorrhage presented on follow-up magnetic resonance imaging (MRI) or computed tomography (CT) but not on baseline CT. We performed binary logistic regression to examine the association between coagulation function and HT. The coagulation indicators were entered into logistic regression analysis as continuous variables (per 1-unit/L increase) and four-categorized variables (with data collapsed into quartiles), respectively.

Results: A total of 1141 patients were included (mean age, 64 ± 15 years; 63.7% males). 102 patients experienced HT (8.9%), of whom 14 patients experienced symptomatic HT (sHT, 1.2%). After adjustment for confounders, TT in the highest quartile is inversely associated with risk of HT (as continuous variable, odds ratio [OR] 0.85; 95% confidence level [CI] 0.73-0.99, P = 0.042; as four-categorized variable, OR 0.36, 95% CI 0.18 - 0.7, P = 0.003). Whether as continuous variables or four-categorized variables, PT, INR, APTT and FIB had no association with HT.

Conclusion: Not the whole process of coagulation function is associated with spontaneous HT. Prolonged TT, which may indicate an extension of the last step of the coagulation process, is independently and inversely associated with spontaneous HT in patients with acute ischemic stroke.

Keywords: Ischemic stroke, hemorrhagic transformation, prothrombin time, activated partial thromboplastin time, international normalized ratio, thrombin time, fibrinogen.

« Previous Next »
[1]
Yaghi S, Willey JZ, Cucchiara B, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2017; 48(12): e343-61.
[http://dx.doi.org/10.1161/STR.0000000000000152] [PMID: 29097489]
[2]
Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 2013; 12(7): 689-705.
[http://dx.doi.org/10.1016/S1474-4422(13)70055-3] [PMID: 23726850]
[3]
Kim BJ, Han MK, Park TH, et al. Low-versus standard-dose Alteplase for ischemic strokes within 4.5 hours: A comparative effectiveness and safety study. Stroke 2015; 46(9): 2541-8.
[http://dx.doi.org/10.1161/STROKEAHA.115.010180] [PMID: 26243232]
[4]
Mehta RH, Cox M, Smith EE, et al. Get with the Guidelines-Stroke Program. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke 2014; 45(8): 2263-9.
[http://dx.doi.org/10.1161/STROKEAHA.114.005019] [PMID: 25070958]
[5]
Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1(5): e259-81.
[http://dx.doi.org/10.1016/S2214-109X(13)70089-5] [PMID: 25104492]
[6]
Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50(4): 309-15.
[http://dx.doi.org/10.1016/j.jacc.2007.01.098] [PMID: 17659197]
[7]
Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002; 87(3): 544-6.
[http://dx.doi.org/10.1055/s-0037-1613042] [PMID: 11916094]
[8]
Wang Y, Li Z, Zhao X, et al. GOLDEN BRIDGE—AIS Investigators. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China: A randomized clinical trial. JAMA 2018; 320(3): 245-54.
[http://dx.doi.org/10.1001/jama.2018.8802] [PMID: 29959443]
[9]
Tan S, Wang D, Liu M, Zhang S, Wu B, Liu B. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol 2014; 261(5): 905-12.
[http://dx.doi.org/10.1007/s00415-014-7297-8] [PMID: 24590407]
[10]
Lindley RI, Wardlaw JM, Sandercock PA, et al. Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis 2004; 13(6): 235-46.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2004.03.003] [PMID: 17903981]
[11]
Beggs S, Salter MW. . SnapShot: Microglia in disease. Cell 2016; 165(5): 1294-e1.
[12]
Rajput PS, Lyden PD, Chen B, et al. Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. Neuroscience 2014; 281: 229-40.
[http://dx.doi.org/10.1016/j.neuroscience.2014.09.038] [PMID: 25261684]
[13]
Lin CC, Lee IT, Wu WB, et al. Thrombin mediates migration of rat brain astrocytes via PLC, Ca2+, CaMKII, PKCα, and AP-1-dependent matrix metalloproteinase-9 expression. Mol Neurobiol 2013; 48(3): 616-30.
[http://dx.doi.org/10.1007/s12035-013-8450-6] [PMID: 23585120]
[14]
Olianas MC, Dedoni S, Onali P. Proteinase-activated receptors 1 and 2 in rat olfactory system: Layer-specific regulation of multiple signaling pathways in the main olfactory bulb and induction of neurite retraction in olfactory sensory neurons. Neuroscience 2007; 146(3): 1289-301.
[http://dx.doi.org/10.1016/j.neuroscience.2007.02.059] [PMID: 17434682]
[15]
Bagoly Z, Szegedi I, Kálmándi R, Tóth NK, Csiba L. Markers of coagulation and fibrinolysis predicting the outcome of acute ischemic stroke thrombolysis treatment: A review of the literature. Front Neurol 2019; 10: 513.
[http://dx.doi.org/10.3389/fneur.2019.00513] [PMID: 31316444]
[16]
Du J, Wang Q, He B, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol 2016; 38(3): 233-9.
[http://dx.doi.org/10.1111/ijlh.12474] [PMID: 26992440]
[17]
Prodan CI, Stoner JA, Cowan LD, Dale GL. Lower coated-platelet levels are associated with early hemorrhagic transformation in patients with non-lacunar brain infarction. J Thromb Haemost 2010; 8(6): 1185-90.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03851.x] [PMID: 20218982]
[18]
Christoforidis GA, Karakasis C, Mohammad Y, Caragine LP, Yang M, Slivka AP. Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: The role of pial collateral formation. AJNR Am J Neuroradiol 2009; 30(1): 165-70.
[http://dx.doi.org/10.3174/ajnr.A1276] [PMID: 18768718]
[19]
Vandelli L, Marietta M, Gambini M, et al. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015; 24(2): 394-400.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.005] [PMID: 25497721]
[20]
Sun X, Berthiller J, Trouillas P, Derex L, Diallo L, Hanss M. Early fibrinogen degradation coagulopathy: A predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis. J Neurol Sci 2015; 351(1-2): 109-14.
[http://dx.doi.org/10.1016/j.jns.2015.02.048] [PMID: 25783009]
[21]
Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 2013; 80(13): 1216-24.
[http://dx.doi.org/10.1212/WNL.0b013e3182897015] [PMID: 23486872]
[22]
Hirano K, Takashima S, Dougu N, et al. Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis 2012; 21(5): 404-10.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2011.08.013] [PMID: 22516429]
[23]
Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35(9): 2123-7.
[http://dx.doi.org/10.1161/01.STR.0000137608.73660.4c] [PMID: 15243150]
[24]
Hudák R, Székely EG, Kovács KR, et al. Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis. PLoS One 2017; 12(7)e0180477
[http://dx.doi.org/10.1371/journal.pone.0180477] [PMID: 28692682]
[25]
Božič Mijovski M. Advances in monitoring anticoagulant therapy. Adv Clin Chem 2019; 90: 197-213.
[http://dx.doi.org/10.1016/bs.acc.2019.01.005] [PMID: 31122609]
[26]
Kong FY, Tao WD, Hao ZL, Liu M. Predictors of one-year disabi-lity and death in Chinese hospitalized women after ischemic stroke. Cerebrovasc Dis 2010; 29(3): 255-62.
[http://dx.doi.org/10.1159/000267852] [PMID: 20029199]
[27]
Ott BR, Zamani A, Kleefield J, Funkenstein HH. The clinical spectrum of hemorrhagic infarction. Stroke 1986; 17(4): 630-7.
[http://dx.doi.org/10.1161/01.STR.17.4.630] [PMID: 3738944]
[28]
de Los Ríos la Rosa F, Khoury J, Kissela BM, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: The Effect of the European Cooperative Acute Stroke Study (ECASS). III Trial Stroke 2012; 43(6): 1591-5.
[http://dx.doi.org/10.1161/STROKEAHA.111.645986] [PMID: 22442174]
[29]
Rao NM, Levine SR, Gornbein JA, Saver JL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: Analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke 2014; 45(9): 2728-33.
[http://dx.doi.org/10.1161/STROKEAHA.114.005135] [PMID: 25096731]
[30]
Sangha N, El Khoury R, Misra V, et al. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 2012; 21(8): 917-e5-8.
[31]
Bohmann F, Mirceska A, Pfeilschifter J, et al. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One 2012; 7(7)e40804
[http://dx.doi.org/10.1371/journal.pone.0040804] [PMID: 22911709]
[32]
Tanaka KA, Key NS, Levy JH. Blood coagulation: Hemostasis and thrombin regulation. Anesth Analg 2009; 108(5): 1433-46.
[http://dx.doi.org/10.1213/ane.0b013e31819bcc9c] [PMID: 19372317]
[33]
Tomczyk M, Suzuki Y, Sano H, Brzoska T, Tanaka H, Urano T. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis. Thromb Res 2016; 143: 28-33.
[http://dx.doi.org/10.1016/j.thromres.2016.04.018] [PMID: 27179129]
[34]
Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38(3): 376-85.
[http://dx.doi.org/10.1016/j.nbd.2010.03.008] [PMID: 20302940]
[35]
De Luca C, Virtuoso A, Maggio N, Papa M. Neuro-coagulopathy: Blood coagulation factors in central nervous system diseases. Int J Mol Sci 2017; 18(10): 2128.
[http://dx.doi.org/10.3390/ijms18102128] [PMID: 29023416]
[36]
Stein ES, Itsekson-Hayosh Z, Aronovich A, et al. Thrombin induces ischemic LTP (iLTP): Implications for synaptic plasticity in the acute phase of ischemic stroke. Sci Rep 2015; 5: 7912.
[http://dx.doi.org/10.1038/srep07912] [PMID: 25604482]
[37]
Bushi D, Ben Shimon M, Shavit Stein E, Chapman J, Maggio N, Tanne D. Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. J Neurochem 2015; 135(6): 1140-8.
[http://dx.doi.org/10.1111/jnc.13372] [PMID: 26390857]
[38]
Ben Shimon M, Lenz M, Ikenberg B, et al. Thrombin regulation of synaptic transmission and plasticity: Implications for health and disease. Front Cell Neurosci 2015; 9: 151.
[http://dx.doi.org/10.3389/fncel.2015.00151] [PMID: 25954157]
[39]
Maggio N, Itsekson Z, Dominissini D, et al. Thrombin regulation of synaptic plasticity: Implications for physiology and pathology. Exp Neurol 2013; 247: 595-604.
[http://dx.doi.org/10.1016/j.expneurol.2013.02.011] [PMID: 23454608]
[40]
Lin CC, Shih CH, Yang YL, et al. Thrombin induces inducible nitric oxide synthase expression via the MAPK, MSK1, and NF-κB signaling pathways in alveolar macrophages. Eur J Pharmacol 2011; 672(1-3): 180-7.
[http://dx.doi.org/10.1016/j.ejphar.2011.10.005] [PMID: 22004609]
[41]
Komotar RJ, Kim GH, Otten ML, et al. The role of complement in stroke therapy. Adv Exp Med Biol 2008; 632: 23-33.
[http://dx.doi.org/10.1007/978-0-387-78952-1_2] [PMID: 19025111]
[42]
Jickling GC, Liu D, Stamova B, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab 2014; 34(2): 185-99.
[http://dx.doi.org/10.1038/jcbfm.2013.203] [PMID: 24281743]
[43]
Wang L, Luo J, He S. Induction of MMP-9 release from human dermal fibroblasts by thrombin: Involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC Cell Biol 2007; 8(1): 14.
[http://dx.doi.org/10.1186/1471-2121-8-14] [PMID: 17480240]
[44]
Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4): 598-603.
[http://dx.doi.org/10.1161/01.CIR.0000046451.38849.90] [PMID: 12566373]
[45]
Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34(1): 40-6.
[http://dx.doi.org/10.1161/01.STR.0000046764.57344.31] [PMID: 12511748]
[46]
Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39(3): 279-91.
[http://dx.doi.org/10.1002/glia.10108] [PMID: 12203394]
[47]
Gillis JC, Wagstaff AJ, Goa KL. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995; 50(1): 102-36.
[http://dx.doi.org/10.2165/00003495-199550010-00008] [PMID: 7588083]
[48]
Marsh EB, Llinas RH, Hillis AE, Gottesman RF. Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation. Eur J Neurol 2013; 20(6): 962-7.
[http://dx.doi.org/10.1111/ene.12126] [PMID: 23521544]
[49]
Kablau M, Kreisel SH, Sauer T, et al. Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Dis 2011; 32(4): 334-41.
[http://dx.doi.org/10.1159/000331702] [PMID: 21921596]
[50]
Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: Rate, predictive factors, and influence on clinical outcome: Results of a prospective multicenter study. Stroke 2008; 39(8): 2249-56.
[http://dx.doi.org/10.1161/STROKEAHA.107.510321] [PMID: 18535273]
[51]
Aggarwal HR, Hassan AE, Rodriguez GJ, Suri MF, Taylor RA, Qureshi AI. Use of intravenous recombinant tissue plasminogen activator in patients with borderline elevation of international normalized ratio. J Vasc Interv Neurol 2013; 6(2): 1-8.
[PMID: 24358409]
[52]
Bembenek JP, Niewada M, Siudut J, Plens K, Członkowska A, Undas A. Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: The impact on clinical outcome. Thromb Haemost 2017; 117(7): 1440-7.
[http://dx.doi.org/10.1160/TH16-12-0954] [PMID: 28382369]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy